Tumor immunity and autoimmunity: A case of Dr. Jekyll and Mr. Hyde

Clinical Immunology

Volumn 100, Issue 2, 2001, Pages 129-133

  Reeves, Westley H ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; IMMUNOSTIMULATING AGENT; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; AUTOIMMUNITY; CANCER GROWTH; CANCER SURVIVAL; EDITORIAL; GENE MUTATION; HUMAN; IMMUNE RESPONSE; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RNA BINDING; TUMOR IMMUNITY;

EID: 0034905290     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1006/clim.2001.5070     Document Type: Editorial

References (44)

1. Human tumor antigens for cancer vaccine development
2. Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model
3. Melanocyte destruction after antigen-specific immunotherapy of melanoma: Direct evidence of T cell-mediated vitiligo
4. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer
5. Onconeural antigens and the paraneoplastic neurologic disorders: At the intersection of cancer, immunity, and the brain
6. Anti-Hu antibodies in patients with small-cell lung cancer: Association with complete response to therapy and improved survival
7. Cloning of a brain protein identified by autoantibodies from a patient with paraneoplastic cerebellar degeneration
8. The onconeural antigen Nova-1 is a neuron-specific RNA-binding protein, the activity of which is inhibited by paraneoplastic antibodies
9. Anti-Hu-associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients
10. HuD, a paraneoplastic encephalomyelitis antigen, contains RNA-binding domains and is homologous to Elav and Sex-lethal
11. Embryonic lethal abnormal visual RNA-binding proteins involved in growth, differentiation, and posttranscriptional gene expression
12. Why is Hu where? Shuttling of early-response-gene messenger RNA subsets
13. ELAV proteins stabilize deadenylated intermediates in a novel in vitro mRNA deadenylation/degradation system
14. AU-rich elements: Characterization and importance in mRNA degradation
15. Ectopic expression of Hel-N1, an RNA-binding protein, increases glucose transporter (GLUT1) expression in 3T3-L1 adipocytes
16. RNA recognition: Towards identifying determinants of specificity
17. Characterization of a cDNA encoding a 34-kDa Purkinje neuron protein recognized by sera from patients with paraneoplastic cerebellar degeneration
18. A role for CD95 ligand in preventing graft rejection
19. A novel cytoplasmic protein with RNA-binding motifs is an autoantigen in human hepatocellular carcinoma
20. Conserved structures and diversity of functions of RNA-binding proteins
21. A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development
22. Transcripts of the insulin-like growth factors I and II in human hepatoma
23. Non-tolerance and autoantibodies to a transgenic self antigen expressed in pancreatic beta cells
24. A human autoimmune protein associated with U1 RNA contains a region of homology that is cross-reactive with retroviral p30gag antigen
25. Autoantibodies define a family of proteins with conserved double-stranded RNA binding domains as well as DNA-binding activity
26. A conserved double-stranded RNA-binding domain
27. Human RNA helicase A is a lupus autoantigen that is cleaved during apoptosis
28. A toll-like receptor recognizes bacterial DNA
29. Activation of target-tissue immune-recognition molecules by double-stranded polynucleotides
30. Activities of adenovirus virus-associated RNAs: Purification and characterization of RNA binding proteins
31. A sequence-specific conformational epitope on U1 RNA is recognized by a unique autoantibody
32. Epitope regions of U1 small nuclear RNA recognized by anti-U1RNA-specific autoantibodies
33. Two small RNAs encoded by Epstein-Barr virus and complexed with protein are precipitated by antibodies from patients with systemic lupus erythematosus
34. Herpesvirus saimiri U RNAs are expressed and assembled into ribonucleoprotein particles in the absence of other viral genes
35. Initiation of autoimmunity to the p53 tumor suppressor protein by complexes of p53 and SV40 large T antigen
36. B cells process and present lupus autoantigens that initiate autoimmune T cell responses
37. Loss of CD23 is a consequence of B-cell activation. Implications for the analysis of B-cell lineages
38. Accumulation of splenic B1a cells with potent antigen-presenting capability in NZM2410 lupus-prone mice
39. Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies
40. DNA vaccination with HuD inhibits growth of a neuroblastoma in mice
41. Dendritic cells as adjuvants for immune-mediated resistance to tumors
42. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease
43. Insulin-dependent diabetes mellitus induced in transgenic mice by ectopic expression of class II MHC and interferon-gamma
44. Costimulator B7-1 confers antigen-presenting-cell function to parenchymal tissue and in conjunction with tumor necrosis factor a leads to autoimmunity in transgenic mice